Guardion Health Sciences GHSI Stock News

Guardion Health Sciences Inc (NASDAQ: GHSI) is running for the top in the market this morning, trading on gains of more than 20% early on. The gains come after the company announced that it has aquired the rights to assets of NutriGuard Research. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GHSI Stock Pops On Acquisition News

In a press release issued early this morning, Guardion Health Sciences announced that through its wholly-owned subsidiary, NutriGuard Formulations, Inc., it has made a key acquisition. The company has acquired certain assets owned by NutriGuard Research, Inc.

In the release, GHSI said that the acquisition became effective on September 20, 2019 and provides a direct-to-customer capability.

The company said that NutriGuard formulates high-quality, scientifically-credible nutraceuticals. These nutraceuticals are designed to supplement diets and assist in treating and preventing disease.

NutriGuard, the company from which the assets were acquired, has been in business for more than three decades. The company only uses pharmaceutical standards to establish safety and efficacy of its products. The goal of the acquisition is to increase NutriGuard’s existing customer base and build on its product platform by making products available to patients directly and through recommendations by their doctors.

As part of the agreement, GHSI said that founding shareholder of NutriGuard, Mark McCarty, will enter into a consulting agreement with Nutriguard Formulations. As such, he will provide consulting services and serve on the as the Director of Research.

In a statement, Mr. McCarty, had the following to offer:

I am very excited about joining forces with Guardion. We are seeing increasing numbers of physicians becoming educated on the value of rational nutraceutical supplementation. Additionally, more and more research studies on the health benefits of nutritional supplements are being published in respected medical journals. With significant clinical data and product-specific scientific evidence now available, many doctors are looking for ways to incorporate therapeutic doses of key supplements into their patients’ standard care.

The above statement was followed up by Michael Favish, CEO and Founder at GHSI. Here’s what he had to offer:

We believe that the NutriGuard acquisition marks just the beginning of the expansion of Guardion’s nutraceutical portfolio. This will enable us to market directly to consumers as well as to their doctors. We are delighted to welcome Mr. McCarty as the Director of Research of NutriGuard Formulations, Inc., and we look forward to working with him as we continue to advance the NutriGuard brand and support our doctor partners and the patients that they serve.

Why This News Is Important

The truth of the matter is that this news is huge for Guardion Health Sciences. At the end of the day, it will give the company a line of market-ready products, offering an opportunity to generate significant revenue.

Moreover, these products are already being purchased in the market and recommended by physicians. Building upon this strong foundation will allow the company to greatly increase shareholder value in a relatively short period of time.

All in all, the news issued by GHSI today is a value add story. With investors having the goal of seeing growth, it’s no surprise to see such a positive reaction in the market.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.